Castle Biosciences (CSTL) Baird Global Healthcare Conference 2025 summary

Portfolio overview and recent developments

• Offers diagnostic tests for melanoma, squamous cell carcinoma, uveal melanoma, and Barrett’s esophagus, with a new atopic dermatitis test expected to launch by year-end.

• TissueCypher and Esopredict tests address risk stratification in gastroenterology, with Esopredict acquired via Previse.

• SciBase collaboration aims to identify atopic dermatitis flares before they occur.

• Maintains strong adjusted gross margins and ended the year with $275 million in cash.

• Medicare contractors accepted reconsideration requests for squamous cell carcinoma test coverage.

Market penetration and growth outlook

• Melanoma test currently reaches about 30-31% of suitable patients, with 55-60% of eligible clinicians having used a derm test in the past year.

• Market penetration analogs suggest potential for further growth, with uveal melanoma test at 85% penetration.

• High single-digit volume growth expected for melanoma test in the near term, with physician conversion slowing as the market matures.

• Seasonality impacts test volumes, with Q2 typically seeing the highest physician encounter days.

• Sales force now focused on melanoma while awaiting reimbursement clarity for squamous cell carcinoma.

Reimbursement and data strategy

• Recent publications provide strong evidence for the clinical and economic value of the squamous cell carcinoma test, including potential Medicare savings of $1 billion.

• Substantial new data developed since initial negative coverage decisions; company expects this to be persuasive for future coverage.

• Administrative acceptance of reconsideration requests is a process milestone, with further review pending.